
Lupin, a pharmaceutical company, has secured tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Apalutamide Tablets, 60 mg, to treat prostate cancer. This approval allows Lupin to market a generic version of Janssen Biotech's Erleada Tablets, 60 mg. The product will be produced at Lupin's Pithampur facility in India. Apalutamide Tablets, 60 mg (Reference Listed Drug: Erleada), recorded an estimated annual US sales figure of $1,185.5 million, according to IQVIA MAT data from July 2023.
Like
Save
Share